HBPCF (Helix BioPharma) Short-Term Debt: $0.26 Mil (As of Apr. 2026)


HBPCF Helix BioPharma Corp HBPCF
28 GF Score
Price $1.71
View Full Analysis

What is Helix BioPharma Short-Term Debt?

Helix BioPharma HBPCF 28 Short-Term Debt is $0.26 Mil as of Apr. 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100.

Helix BioPharma's Short-Term Debt for the quarter that ended in Apr. 2026 was $0.26 Mil.

Helix BioPharma's quarterly Short-Term Debt increased from Oct. 2025 ($0.25 Mil) to Jan. 2026 ($0.26 Mil) but then stayed the same from Jan. 2026 ($0.26 Mil) to Apr. 2026 ($0.26 Mil).

Helix BioPharma's annual Short-Term Debt stayed the same from Jul. 2023 ($0.00 Mil) to Jul. 2024 ($0.00 Mil) but then increased from Jul. 2024 ($0.00 Mil) to Jul. 2025 ($0.25 Mil).

Helix BioPharma Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Helix BioPharma Short-Term Debt Related Terms

Helix BioPharma Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Helix BioPharma's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix BioPharma Short-Term Debt Chart

Helix BioPharma Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.62 1.91 0.00 0.00 0.25

Helix BioPharma Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.25 0.25 0.26 0.26
HBPCF
28GF Score
Helix BioPharma Corp HBPCF
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.26 Mil mean?
Helix BioPharma (HBPCF) has a Short-Term Debt of $0.26 Mil as of Apr. 2026.
Is Helix BioPharma's Short-Term Debt too high?
Helix BioPharma's current Short-Term Debt is $0.26 Mil. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's Short-Term Debt compare to VRTX and REGN?
Helix BioPharma's Short-Term Debt of $0.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Helix BioPharma's current Short-Term Debt is $0.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current Short-Term Debt of $0.26 Mil. The current Short-Term Debt is $0.26 Mil. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current Short-Term Debt is $0.26 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helix BioPharma Business Description

Other Exchanges HBP0:GermanyHBP:Canada
Address 40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score

Get the complete analysis for HBPCF

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price